NCT04906044View on ClinicalTrials.gov

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

October 18, 2023

Study Completion Date

June 1, 2026

Conditions
TislelizumabLocally Advanced Rectal CancerTotal Neoadjuvant TreatmentPD-1
Interventions
DRUG

Sintilimab

Sintilimab combined withTotal Neoadjuvant Treatment

Trial Locations (1)

130021

First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT04906044 - Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter